Posted in | News | Uranium

Macusani Yellowcake Releases Additional Assay Results from Kihitian Property

Macusani Yellowcake has pronounced further assay results from the drill campaign conducted at the two platforms, PT-CH2 and PT-CH17. These platforms are located at the Chilcuno Chico region of the Kihitian Property in Peru.

The exploration targeting the deep Manto B zone has cut an average grade of 2,042 ppm U3O8 over 11 m. This intersection signifies the excellent part of an intersection from 74 to 101 m with a weighted average grade of 862 ppm U3O8.

The CEO and President of the company, has commented that the drill program performed at Kihitian property continues to outline the high-grade uranium at the deep Manto B zone. So far, the exploration has shown consistent, excellent values of uranium having good thickness and the company is expecting that the Manto B zone could expand into an economic underground deposit."

The location of the platform 17 is 120 m to adits’ northwest direction, which were explored during the 1980’s by IPEN. Platform 2 is sited 200 m to the northern part of the same adits. CH17-TNW and CH2-TSE platforms are situated 210 m apart and adjacent to the access road constructed by Macusani to the drill site, on a low altitude zone wherein the Manto A was eroded completely and Manto B is nearer to the surface.

The Manto B zone has encountered an average of 0.0862% U3O8 over 27 m and 0.2042% U3O8 over 11 m from the surface in the bore hole CH17-SW. Also, it has yielded 0.0699% U3O8 over 5 m in the bore hole CH2-TSE.

The company drilled the bore hole CH2-TSE, which inclined at 55° towards South-East, and the bore hole CH17-TNW that was inclining at 55° towards North-West.

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 18). Macusani Yellowcake Releases Additional Assay Results from Kihitian Property. AZoMining. Retrieved on November 23, 2024 from https://www.azomining.com/News.aspx?newsID=4713.

  • MLA

    Scanlon, Joel. "Macusani Yellowcake Releases Additional Assay Results from Kihitian Property". AZoMining. 23 November 2024. <https://www.azomining.com/News.aspx?newsID=4713>.

  • Chicago

    Scanlon, Joel. "Macusani Yellowcake Releases Additional Assay Results from Kihitian Property". AZoMining. https://www.azomining.com/News.aspx?newsID=4713. (accessed November 23, 2024).

  • Harvard

    Scanlon, Joel. 2019. Macusani Yellowcake Releases Additional Assay Results from Kihitian Property. AZoMining, viewed 23 November 2024, https://www.azomining.com/News.aspx?newsID=4713.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.